Clinical trials: Contrast Agent
- Condition Contrast Agent
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hypothyroidism
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™)…
- Trial name
- NCT03631771
- Testing
- Iohexol, Iodixanol, Iopromide
- Sponsor
- GE Healthcare
Focal Liver Lesions
Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging
Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas.
- Trial name
- NCT06639828
- Testing
- Contrast-Enhanced Ultrasound
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- GE Healthcare
Myopia
Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast
Prospective, randomized, subject-masked 3-arm clinical study to assess the pediatric acceptability across three iterations of a novel spectacle lens design.
- Trial name
- WALNUT (NCT03761758)
- Testing
- Spectacle lenses
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Contrast Enhancement in Magnetic Resonance Imaging, Children
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
Researchers are looking for a better way to help children under the age of 18 with any known or suspected problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- NCT05915026
- Testing
- Gadoquatrane (BAY1747846)
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 105 people
- Sponsor
- Bayer
Renal Insufficiency
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not…
- Trial name
- NCT00773409
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Bracco Diagnostics, Inc
Diagnostic Self Evaluation, Central Nervous System Diseases
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine.
- Trial name
- SENTIO (NCT01211873)
- Testing
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 416 people
- Sponsor
- Guerbet
Magnetic Resonance Imaging
Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)
The main purpose of this study is to collect data on the way gadobutrol is taken into, moves around, and is eliminated from, the body of children aged 0 to less than 2 years.
- Trial name
- NCT01544166
- Testing
- Gadobutrol (Gadavist, BAY86-4875)
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bayer
Contrast-enhanced MRI With Dotarem
Post-marketing Surveillance Study for Evaluation of Dotarem Safety
Guerbet conducted a non-interventional post-marketing surveillance study on its Magnetic Resonance Imaging (MRI) contrast agent Dotarem (gadoteric acid/gadoterate meglumine).
- Trial name
- NCT03048006
- Testing
- MRI with Dotarem
- Volunteers
- 44,456 people, healthy volunteers welcome
- Sponsor
- Guerbet
Myopia, Child Myopia Progression
Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children
This prospective, single-center study aims to evaluate the efficacy and safety of MiYOSMART iQ spectacle lenses with DIMS (Defocus Incorporated Multiple Segments) and Triple Enhanced Design (TED) technology in slowing myopia…
- Trial name
- NCT07387159
- Testing
- MiYOSMART iQ spectacle lenses
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Hoya Lens Rus LLC
Contrast Enhancement in Magnetic Resonance Imaging
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
This is an observational study, in which data associated with the wastage with the use of Gadavist single-dose vials, as compared to the wastage associated with the use of the Gadavist imaging bulk packages (IBP) used for…
- Trial name
- NCT05350189
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- 2 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Bayer
Liver Neoplasms, Adenoma
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Medical records are reviewed to obtain information about the use of a MRI diagnostic imaging agent (contrast agent) called Primovist/Eovist in children older than 2 months and less than 18 years.
- Conditions
- Liver Neoplasms, Adenoma, Carcinoma, Liver Abscess
- Trial name
- NCT01043523
- Testing
- Gadoxetic Acid Disodium (Eovist, BAY86-4873)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Magnetic Resonance Imaging, Image Enhancement
Drug Use Investigation of Gadovist.
The objectives of this study are to investigate the safety and effectiveness of Gadovist.
- Trial name
- NCT02540967
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- Japan
- Volunteers
- 3,357 people
- Sponsor
- Bayer
Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality
Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
Study to determine the safety and appropriate dosage of OPTISON in pediatric participants since OPTISON has been tested in adult participants only during the clinical development
- Trial name
- NCT03740997
- Testing
- Optison
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- GE Healthcare
Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast
Lag of Accommodation With DOT Spectacle Lenses
The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.
- Trial name
- ASH (NCT04700111)
- Testing
- DOT Pattern, Control Spectacles
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Pathological Processes
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
The objective of this study is to characterize the safety, efficacy and pharmacokinetic profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient population.
- Trial name
- NCT01092754
- Testing
- MRI, Gadoversetamide
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Guerbet
Hypothyroidism
Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
This study will estimate the incidence of hypothyroidism in a pediatric population of children under age 4, based on data from the US-based Kaiser Permanente Northern California database, which were exposed to iodinated contrast…
- Trial name
- NCT02959827
- Testing
- Iodinated contrast agents
- Where
- United States
- Volunteers
- 2,320 people
- Sponsor
- Bayer
Hypothyroidism
Thyroid Function of Pediatric Subjects Following Isovue® Administration
This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the…
- Trial name
- NCT03779906
- Testing
- Isovue
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bracco Diagnostics, Inc
AKI, Contrast-induced Nephropathy
Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization
This study will collect high-quality randomized controlled data across the U.S. from practicing cardiologists performing invasive/interventional procedures and determine how they currently manage patients at risk for CIN and how…
- Trial name
- NCT04266834
- Testing
- Experimental Arm
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Rheumatoid Arthritis
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
- Trial name
- NCT05576051
- Testing
- patterns of use of combination therapy and monotherapy
- Where
- United States
- Volunteers
- 9,159 people
- Sponsor
- Pfizer
Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
Study With Oral Isovue in Abdominopelvic CT
This is a retrospective clinical study with prospectively designed blinded evaluation of CT images in adult and pediatric patients who underwent CT examinations of the abdomen and pelvis and were orally administered a solution of…
- Trial name
- NCT04453059
- Testing
- Iopamidol
- Where
- United States
- Volunteers
- 218 people
- Sponsor
- Bracco Diagnostics, Inc